AMGN reports Q1 2026 results on April 30, heading into the release with one notable wrinkle: short interest has jumped sharply in the past week even as the stock barely moved.
Short sellers have been quietly rebuilding positions. SI climbed 18% over the week to reach 2.48% of the free float — still modest in absolute terms, but the velocity is striking. The move reverses a sharper unwind that had cut SI nearly in half through March and early April, when it dropped from around 3.1% of float in mid-March to just 1.8% in early April. The re-accumulation started around April 23 and accelerated into the close of April 28. Despite all that activity, the borrow market remains entirely relaxed — the cost to borrow is running at just 0.41% annually, and availability is loose, meaning new short positions can be added cheaply and easily. The ORTEX short score has edged up to 36.9 over the past week, still low in the overall universe, but rising at a pace worth noting into earnings.
Options positioning is broadly neutral heading into the print. The put/call ratio closed at 0.82 on April 28, essentially in line with its 20-day average of 0.81, with a z-score of just 0.31 — no meaningful skew toward protection or speculation. That places the reading comfortably in the middle of its 52-week range (0.62 low, 1.11 high). Unlike the shorts, which are clearly leaning cautious, options traders appear unmoved by the earnings setup. The two signals diverge: positioning in the lending market is growing more cautious, but the options market has not flinched.
The Street's view on AMGN is broadly held-and-wait. The consensus is a Hold, with the mean analyst price target at $352.73 against a current price of $339.57 — roughly 4% implied upside, not enough to generate excitement. The clearest recent action came from UBS, which raised its target to $400 while maintaining its Buy rating on April 13. Morgan Stanley moved in the opposite direction of conviction, lifting its Equal-Weight target from $309 to $326 on April 10. Canaccord initiated coverage at Hold with a $366 target on April 21 — the third firm to set up at neutral-to-cautious in recent weeks. The valuation picture is measured: the trailing PE is near 15x and the EV/EBITDA near 10.6x, both drifting slightly lower over the past month, suggesting no meaningful re-rating either way. Factor scores reflect the same ambivalence — the dividend score is a standout at the 89th percentile, but EPS surprise ranks in just the 23rd percentile, and forward earnings momentum is barely above average at the 53rd-54th percentile.
The bull and bear cases converge on the same themes, which rarely makes for a decisive setup. Bulls point to MariTide and olpasiran as potential pipeline catalysts and note that Q4 2025 showed real revenue momentum — $9.9 billion against $9.1 billion a year earlier, with net income more than doubling. Bears flag the patent cliff on key franchises, limited near-term pipeline visibility, and ongoing biosimilar and generic competition. The bear target of $318 sits well below the current price, while the most aggressive bull case runs to $432. With 19 Hold ratings and no dominant direction from recent analyst moves, the market is effectively asking the Q1 print to break the deadlock.
Peers have not offered much shelter this week. REGN fell 2.1% and GILD dropped 3.0% over the same period, while INCY managed a 1.6% gain — suggesting sector weakness rather than AMGN-specific pressure behind the 1.5% weekly decline to $339.57. The Q4 2025 print delivered a one-day move of +6.2%, which is a useful reference point: last quarter surprised meaningfully to the upside, and the stock responded. With SI re-accumulating ahead of tomorrow's release, the setup going into April 30 is whether the Q1 print can repeat that dynamic, or whether the fresh short interest proves better-placed this time.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
